Skip to main content
. Author manuscript; available in PMC: 2021 Sep 22.
Published in final edited form as: Cancer Res. 2020 Dec 22;81(4):885–897. doi: 10.1158/0008-5472.CAN-19-3219

Figure 6. Nilotinib prolongs survival of mice bearing pancreatic cancer by impeding the development of muscle wasting.

Figure 6.

Five days after orthotopic implantation of KPC cells to mice, nilotinib (0.5 mg/kg/day) or DMSO were administered intraperitoneally until all tumor-bearing mice reached predetermined end point (n = 7). (A) Nilotinib prolongs survival of mice bearing KPC tumor. Survival of KPC tumor-bearing mice was recorded and analyzed using the Kaplan–Meier survival curve. (B) Nilotinib impedes the loss of muscle strength in mice bearing KPC tumor. Forelimb grip strength of the mice was monitored over the course of the survival study. Data were analyzed by 2-way ANOVA. * signifies a statistically significant difference (p < 0.05).